Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $102.7 million.

  • Protagonist Therapeutics' Long-Term Investments fell 1038.13% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year decrease of 1038.13%. This contributed to the annual value of $140.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Protagonist Therapeutics' Long-Term Investments stood at $102.7 million, which was down 1038.13% from $102.5 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Long-Term Investments peaked at $140.3 million during Q4 2024, and registered a low of $2.0 million during Q3 2023.
  • Moreover, its 4-year median value for Long-Term Investments was $70.4 million (2021), whereas its average is $68.8 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Long-Term Investments soared by 563000.0% in 2024, and later crashed by 1038.13% in 2025.
  • Quarter analysis of 4 years shows Protagonist Therapeutics' Long-Term Investments stood at $38.2 million in 2021, then plummeted by 94.76% to $2.0 million in 2023, then soared by 6915.0% to $140.3 million in 2024, then fell by 26.8% to $102.7 million in 2025.
  • Its last three reported values are $102.7 million in Q3 2025, $102.5 million for Q2 2025, and $123.5 million during Q1 2025.